Clinical presentation and patterns of care for short-term survivors of malignant glioma
- 254 Downloads
Palliative care provision for patients with high-grade malignant glioma is often under-utilised. Difficulties in prognostication and inter-patient variability in survival may limit timely referral. This study sought to (1) describe the clinical presentation of short-term survivors of malignant glioma (survival time <120 days); (2) map their hospital utilisation, including palliative and supportive care service use, and place of death; (3) identify factors which may be important to serve as a prompt for palliative care referral. A retrospective cohort study of incident malignant glioma cases between 2003–2009 surviving <120 days in Victoria, Australia was undertaken (n = 482). Cases were stratified according to the patient’s survival status (dead vs. alive) at the end of the diagnosis admission, and at 120 days from diagnosis. Palliative care was received by 78 % of patients who died during the diagnosis admission. Only 12 % of patients who survived the admission and then deteriorated rapidly dying in the following 120 days were referred to palliative care in their hospital admission, suggesting an important clinical subgroup that may miss out on being linked into palliative care services. The strongest predictor of death during the diagnosis admission was the presence of cognitive or behavioural symptoms, which may be an important prompt for early palliative care referral.
KeywordsMalignant Glioma Palliative care Symptom burden Population cohort study Coded hospital data Adjusted odds ratio
This study was supported by translational cancer research Grant [EO109_29] from the Victorian Cancer Agency of the Victorian State Government Department of Health. The authors would like to acknowledge the time and expertise of the study advisory group who ensured the methodology, results, and interpretation of findings were clinically grounded: Ros Aylot, Amanda Bolleter, Dr Dianne Clifton, Dr Jeremy Couper, Dr Michael Dally, Prof Mark Rosenthal, Dr Peter Sherwen, and Jane Staker.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Lin E, Rosenthal MA, Le BH, Eastman P (2012) Neuro-oncology and palliative care: a challenging interface. Neuro-Oncology 14(suppl 4):iv3–iv7Google Scholar
- 2.Philip J, Collins A, Brand CA, Gold M, Moore G, Sundararajan V et al. (2013) Health care professionals’ perspectives of living and dying with primary malignant glioma: Implications for a unique cancer trajectory. Palliat Support Care. doi: 10.1017/S1478951513000576
- 7.Collins A, Lethborg C, Brand C, Gold M, Moore G, Sundararajan V et al (2014) The challenges and suffering of caring for people with primary malignant glioma: qualitative perspectives on improving current supportive and palliative care practices. BMJ Support Palliat Care 4(1):68–76PubMedCrossRefGoogle Scholar
- 18.Central Nervous System Tumour Group Brain Tumour Patient Pathway. Victoria: WCMICS: Western and Central http://www.wcmics.org/docs/CNS-BrainTumourPatientPathwayProjectReport.pdf. Accessed 23 Mar 2014
- 30.Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA J Am Med Assoc 284(19):2476–2482Google Scholar